Total Funding
59
86
Total FundingVenture - Series Unknown raised
Growth Score
-1 pts
Heat Score
5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
8763
MimiVax is a developer of immunotherapeutic vaccines and targeted therapies used to control tumor growth and recurrence.
- Scott E. Friedman: Board Member, Co-founder, and General Counsel
- Robert Fenstermaker: Chief Medical Officer
About the Company
MimiVax is a privately-held, clinical-stage biotechnology company that focuses on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. Its vaccines use survivin-targeting technology to target a cell-survival protein present in most cancers that enable healthcare providers to cure
their patients.
The company was founded in 2012 and is headquartered in Buffalo, New York.
